I’m leaving for the conference today, yay! I’m really excited about this one. There are so many important issues in this area with stem cells right now, especially with the Gordie Howe story. So much of the stem cell field is unregulated right now the second you get out of the U.S., and that’s an issue that has to be addressed. Here’s the link to the pdf of the agenda for the day:
Symposium Flyer 2.12.15 (1)
Now that the holidays are finally over, I’m really getting some of these stem cell activities in motion. Yay! That includes a wonderful opportunity to go to UC-Davis for this Feb 12th event. They might still have some spaces left, so if anyone reading this is within any reasonable drive of Davis, I URGE you to check out Paul Knoepfler’s post on the subject. Here’s the piece on his blog, and that’s how I found out about it. What it makes this so exciting is that they’re apparently going to be talking about some REAL, GENUINE ethical issues. To wit… what on earth are we going to do about all of those stem cell clinics popping up in various and assorted countries? You know, the ones with the weird, dubious, expensive treatments that the FDA would never approve in a gazillion years? And while we’re on the subject, when is the FDA going to do anything about regulating, say, $10,000 stem cell creams? And what about those “Right to Try” laws? They passed in four states in November, but what is the federal government going to do, if anything? What should they do?
Anyway… it looks like it’s going to be an amazing seminar, and I’ll come back with lots and lots and lots of notes!! 🙂
Posted in Stem cell ethics
Tagged Alison Sorkin, cures, embryonic stem cells, hope for terminally ill, hype, induced pluripotent stem cells, investigational drugs, Leigh Turner, Mary Ann Chirba, paul knoepfler, Richard Garr, Timothy Caulfield, uc davis, university of california, university of california davis
So today was the wrap party for NaNo (National Novel Writing Month,) and I read from the stem cell book I worked on all through November. (Yep, it’s the planned book on this site, And the Blind Shall See: The Promise of Stem Cell Cures.) It came from the section on working in hospice with Alzheimer’s patients. People were really touched (and I’m not going to try to claim that it was from the amazing writing quality!) No, it’s because everyone can relate to the desperate need for cures for degenerative diseases. And yet it’s basically a situation where even the most educated people never know almost anything about what’s really going on with truly effective stem cell research (like Ocata’s.) If you’ve ever lived with the situation of caring for a relative who has a degenerative disease like Alzheimer’s, you know how utterly draining it is, how much it takes out of you. I saw it every single day when I worked hospice. And it isn’t just older people, believe me. There was one woman I knew who died of MS when she was only thirty-six years old. I’m going to put up a series of posts on working with patients who had degenerative diseases, and there’s quite a range of those. Alzheimer’s, other types of dementia, MS, COPD, severe arthritis, and on and on and on. These might not be the most cheerful stories in the world– but we’re working on a happy ending through regenerative medicine! 🙂
Posted in The diseases stem cells could cure
Tagged Alzheimer's, arthritis, coping, cures, dementia, embryonic stem cells, hope for terminally ill, hospice, multiple sclerosis, ocata, patients, regenerative medicine
So, I was posting a summary for my book on the NaNoWriMo Facebook page, thinking that it sounded over the top… stem cell-based cures for horrible incurable diseases within 2-10 years, that kind of thing… well….
There’s no link for this, because it is insider info from shareholders who went to Ocata’s quarterly meeting in Boston, which was not open to the public. (There is a LOT about Ocata in the book– they’re the biotech company that just changed their name from Advanced Cell Technology.) Ocata is the company developing the first cure (or even treatment!) for age-related macular degeneration, a disease that slowly causes blindness for 30 million people in the U.S. and Europe alone. The interim published results for the clinical trials have looked great, but as far as when this treatment might actually come to market… it’s everybody’s guess.
But in the quarterly meeting… several attendees have all said the same thing. The drug already has orphan treatment approval for a genetic disease caused Stargardt’s, which has exactly the same effects and eventually causes blindness. But it attacks much younger people, including children as young as six. (Yep, six years old.) AND… the CEO of Ocata said that the drug will be available in the U.K. in 2018. We don’t have absolute confirmation of this yet. But it’s apparently what was officially said at that meeting.
One of the lines of thought on the forums is that the date might be earlier for AMD approval in the U.S, even quite a bit earlier if the drug is fast tracked here… we just don’t know. But this is INCREDIBLE!!!~ There has never ever been any kind of treatment for Stargardt’s before, and now there will be, and it will be STEM CELL BASED. As of now, that will be the first drug approved anywhere in the WORLD that is embryonic stem cell based.
YES! IT’S THE START OF A NEW ERA IN MEDICINE!!! And it will be in the book!
(sorry about the capslock…
Posted in Great News
Tagged advanced cell technology, amd, cure for blindness, cures, embryonic stem cells, investigational drugs, miracles, ocata, robert lanza, stargardt, stargardt's, stem cell, stem cells, treatments, trials